With Iomab-B making great strides in its pivotal Phase 3 trial and continued expansion of our best-in-class CD33 program we are increasingly focused on transforming our exoskeleton of a commercial supply chain to a leading, fully-integrated commercial supply chain that is supplying important therapies to the leading medical centers throughout the U.S. SNMMI provides us with key insights and interactions that will allow us to achieve this important business objective. We look forward to building on the momentum we create at the annual meeting as we work to build an independent, self-sustaining Company focused on targeted conditioning for bone marrow transplant." About Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells.